Bangladesh was due to graduate from the United Nations list of Least Developed Countries (LDCs) on 24 November 2026. In 2026 the government sought a three-year deferral, and it was approved: graduation is now scheduled for 24 November 2029 (Nepal's graduation was deferred on the same timetable).

For the pharmaceutical sector, this date matters more than for almost any other industry, because it is tied to how Bangladesh applies patent protection to medicines.

Why LDC status matters for medicine patents

Under the WTO's TRIPS Agreement, least developed countries benefit from a transition period for pharmaceutical products: they are not required to grant or enforce patents (or protect undisclosed test data) for pharmaceutical products until 1 January 2033, or until they cease to be an LDC, if earlier.

Bangladesh's generic medicines industry, which supplies most of the domestic market and exports to well over a hundred countries, has grown within that flexibility. Once Bangladesh graduates, the LDC-specific transition period no longer applies, unless further transition arrangements are agreed internationally.

What the deferral changes

  • More time to prepare, not a cancellation. The policy direction is unchanged; the date has moved to November 2029.
  • The Patents Act, 2022 is already in force, with a 20-year patent term from filing, so the legal framework for patent protection exists today.
  • The window to act is now about three years, which is short for product pipelines, licensing negotiations and regulatory planning.

What local manufacturers should do before 2029

  1. Map exposure. Identify which products in your portfolio, and in your pipeline, may be covered by patents or pending applications in Bangladesh and in your export markets.
  2. Run freedom-to-operate reviews for high-value molecules, combinations and formulations.
  3. Watch patent filings at DPDT for products you make or plan to make.
  4. Consider licensing and voluntary access arrangements early, while you still have negotiating time.
  5. Build your own IP: process improvements, new formulations and delivery systems can be patentable and give you assets of your own.
  6. Brief management and regulatory teams so product launches after 2029 are planned with patents in mind.

What foreign originator companies should do

  1. Review your Bangladesh patent filings and pending applications for key products, and consider filing for new ones under the Patents Act, 2022.
  2. Remember Bangladesh is not in the PCT. File nationally, claiming Paris Convention priority within 12 months of your first filing.
  3. Plan enforcement strategy for after graduation, including how you will monitor the market.
  4. Engage local counsel early, because examination at DPDT takes time.

Frequently asked questions

When will Bangladesh graduate from LDC status?

After a three-year deferral approved in 2026, Bangladesh is scheduled to graduate on 24 November 2029 instead of 24 November 2026.

Does Bangladesh grant pharmaceutical patents now?

Bangladesh has a modern patent law, the Patents Act, 2022. As an LDC it benefits from the TRIPS transition period for pharmaceutical products, which runs until 2033 or until graduation, whichever is earlier. How specific products are treated depends on the law and DPDT practice at the time, so take advice on individual products.

What happens to generic medicines after graduation?

Graduation ends the LDC-specific TRIPS flexibility for pharmaceuticals unless further transition measures are agreed. Generic manufacturers should review patent exposure and freedom to operate well before November 2029.

Is Bangladesh a member of the PCT?

No. Patent applications are filed directly at DPDT, usually claiming Paris Convention priority within 12 months.

We advise both local manufacturers and foreign originators on pharmaceutical IP in Bangladesh. See patent filing in Bangladesh or read our earlier analysis, Pharmaceutical Patents: Impacts on Bangladesh After LDC Graduation.